.Completing interests.R.S., M.S., H.G. and A.A.R. are organizers of the 1M1M project. H.G. as well as A.A.R. are actually panel of supervisors members and also R.S., M.S. and also A.A.R. are members of the clinical advising committee of N1C. A.A.R. divulges work by LUMC, which has patents on exon-skipping modern technology, some of which has actually been actually licensed to BioMarin as well as subsequently sublicensed to Sarepta. As co-inventor of a few of these licenses, A.A.R. was qualified to a share of nobilities. A.A.R. better divulges working as specialist for PTC Rehabs, Sarepta Therapeutics, Regenxbio, Dyne Therapeutics, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. Over the last 5 years, A.A.R. additionally conducted consulting for Alpha Anomeric. A.A.R. additionally states membership of the clinical advisory boards of Eisai, Hybridize Therapeutics, Muteness Therapies, Sarepta Therapies, Sapreme as well as Mitorx. Over the last 5 years, A.A.R. was likewise a clinical advisory board member for ProQR. Reimbursement for A.A.R. u00e2 s consulting and advising activities is spent to LUMC. Previously 5 years, LUMC likewise acquired audio speaker honoraria coming from PTC Rehabs, Alnylam Netherlands, Italfarmaco and also Pfizer as well as cashing for arrangement research coming from Sapreme, Eisai, Galapagos, Synaffix and also Alpha Anomeric. Task funding is obtained coming from Sarepta Rehabs as well as Entrada using unregulated gives. H.G. possesses nothing to divulge in regard to the topics dealt with within this manuscript. Previously 5 years, he has actually additionally obtained consultancy honoraria coming from UCB. M.S. got working as a consultant gratuity from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and also Solaxa in the past 5 years, all unrelated to today manuscript. R.S. has nothing at all to reveal in relation to the subjects dealt with in this manuscript. She has acquired speaker and/or working as a consultant gratuity or even funding additions from Abbvie, Bial, STADA as well as Everpharma previously 5 years.